Search Results - Paul Workman
- Showing 1 - 11 results of 11
-
1
-
2
-
3
Co-crystalization and in vitro biological characterization of 5-aryl-4-(5-substituted-2-4-dihydroxyphenyl)-1,2,3-thiadiazole Hsp90 inhibitors. by Swee Y Sharp, S Mark Roe, Egidijus Kazlauskas, Inga Cikotienė, Paul Workman, Daumantas Matulis, Chrisostomos Prodromou
Published in PLoS ONE (2012-01-01)Get full text
Article -
4
The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage. by Shane Zaidi, Martin McLaughlin, Shreerang A Bhide, Suzanne A Eccles, Paul Workman, Christopher M Nutting, Robert A Huddart, Kevin J Harrington
Published in PLoS ONE (2012-01-01)Get full text
Article -
5
Fadraciclib (CYC065), a novel CDK inhibitor, targets key pro-survival and oncogenic pathways in cancer. by Sheelagh Frame, Chiara Saladino, Craig MacKay, Butrus Atrash, Peter Sheldrake, Edward McDonald, Paul A Clarke, Paul Workman, David Blake, Daniella Zheleva
Published in PLoS ONE (2020-01-01)Get full text
Article -
6
In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells. by Nada M S Al-Saffar, Alice Agliano, Lynley V Marshall, L Elizabeth Jackson, Geetha Balarajah, Jasmin Sidhu, Paul A Clarke, Chris Jones, Paul Workman, Andrew D J Pearson, Martin O Leach
Published in PLoS ONE (2017-01-01)Get full text
Article -
7
Lactate and choline metabolites detected in vitro by nuclear magnetic resonance spectroscopy are potential metabolic biomarkers for PI3K inhibition in pediatric glioblastoma. by Nada M S Al-Saffar, Lynley V Marshall, L Elizabeth Jackson, Geetha Balarajah, Thomas R Eykyn, Alice Agliano, Paul A Clarke, Chris Jones, Paul Workman, Andrew D J Pearson, Martin O Leach
Published in PLoS ONE (2014-01-01)Get full text
Article -
8
Molecular and phenotypic characterisation of paediatric glioma cell lines as models for preclinical drug development. by Dorine A Bax, Suzanne E Little, Nathalie Gaspar, Lara Perryman, Lynley Marshall, Marta Viana-Pereira, Tania A Jones, Richard D Williams, Anita Grigoriadis, Gilles Vassal, Paul Workman, Denise Sheer, Rui M Reis, Andrew D J Pearson, Darren Hargrave, Chris Jones
Published in PLoS ONE (2009-01-01)Get full text
Article -
9
Mechanism-based screen for G1/S checkpoint activators identifies a selective activator of EIF2AK3/PERK signalling. by Simon R Stockwell, Georgina Platt, S Elaine Barrie, Georgia Zoumpoulidou, Robert H Te Poele, G Wynne Aherne, Stuart C Wilson, Peter Sheldrake, Edward McDonald, Mathilde Venet, Christelle Soudy, Frédéric Elustondo, Laurent Rigoreau, Julian Blagg, Paul Workman, Michelle D Garrett, Sibylle Mittnacht
Published in PLoS ONE (2012-01-01)Get full text
Article -
10
Structural insights into human brachyury DNA recognition and discovery of progressible binders for cancer therapy by Joseph A. Newman, Angeline E. Gavard, Nergis Imprachim, Hazel Aitkenhead, Hadley E. Sheppard, Robert te Poele, Paul A. Clarke, Mohammad Anwar Hossain, Louisa Temme, Hans J. Oh, Carrow I. Wells, Zachary W. Davis-Gilbert, Paul Workman, Opher Gileadi, David H. Drewry
Published in Nature Communications (2025-02-01)Get full text
Article -
11
Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases by Paul A Clarke, Maria-Jesus Ortiz-Ruiz, Robert TePoele, Olajumoke Adeniji-Popoola, Gary Box, Will Court, Stephanie Czasch, Samer El Bawab, Christina Esdar, Ken Ewan, Sharon Gowan, Alexis De Haven Brandon, Phillip Hewitt, Stephen M Hobbs, Wolfgang Kaufmann, Aurélie Mallinger, Florence Raynaud, Toby Roe, Felix Rohdich, Kai Schiemann, Stephanie Simon, Richard Schneider, Melanie Valenti, Stefan Weigt, Julian Blagg, Andree Blaukat, Trevor C Dale, Suzanne A Eccles, Stefan Hecht, Klaus Urbahns, Paul Workman, Dirk Wienke
Published in eLife (2016-12-01)Get full text
Article